Get the Stockscreener App
10.75
1.65%
-0.18
After Hours:
10.69
-0.06
-0.56%
Delcath Systems Inc stock is traded at $10.75, with a volume of 512.61K.
It is down -1.65% in the last 24 hours and down -20.96% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$10.93
Open:
$10.88
24h Volume:
512.61K
Relative Volume:
0.79
Market Cap:
$374.38M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.8121
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
-5.70%
1M Performance:
-20.96%
6M Performance:
-31.09%
1Y Performance:
+24.71%
1-Day Range:
$10.69
$11.17
1-Week Range:
$10.69
$11.67
52-Week Range:
$7.1701
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
10.75 | 380.65M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
What catalysts could drive Delcath Systems Inc. stock higher in 2025Smart Portfolio Watchlist To Watch Now - jammulinksnews.com
Visual analytics tools that track Delcath Systems Inc. performanceProfit Target Planning with Exit Confidence - Newser
Why Delcath Systems Inc. stock attracts strong analyst attentionReliable Alerts for Daily Stock Movers Released - metal.it
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Statistical indicators supporting Delcath Systems Inc.’s strengthAlpha Stock Picks with Chart Confirmation - Newser
Delcath Systems to Participate at the Canaccord Genuity 45th Ann - GuruFocus
Delcath Systems: Pioneering Growth in Interventional Oncology Amid Strategic and Regulatory Momentum - AInvest
Delcath Systems Secures Spot at Elite Canaccord Growth Conference, Key Investor Presentation Coming - Stock Titan
Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com
Intrahepatic Cholangiocarcinoma Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bay - Barchart.com
Screener Results Flag Delcath Systems Inc. as OversoldTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Visualizing Delcath Systems Inc. stock with heatmapsFree Daily Momentum Screener With Alerts - Newser
Will Delcath Systems Inc. continue its uptrendFree Entry Zone Strategy for Consistent Profit - Newser
How Delcath Systems Inc. stock performs during market volatilityDaily Swing Candidate Analysis with Chart Patterns - Newser
What makes Delcath Systems Inc. stock price move sharplyAI Powered Tips With High Returns - jammulinksnews.com
What institutional investors are buying Delcath Systems Inc. stockBreakthrough profits - jammulinksnews.com
Does Delcath Systems Inc. stock perform well during market downturnsSuperior trading gains - jammulinksnews.com
Delcath Systems Inc. Company’s Quarterly Earnings Growth: What the Numbers SayBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Why is Delcath Systems Inc. stock attracting strong analyst attentionBuild wealth faster with consistent investment plans - jammulinksnews.com
Delcath Systems announces inducement grants - Medical Buyer
How to build a custom watchlist for SITC Risk Balanced Picks for Safer Trading - Newser
Will Delcath Systems Inc. continue its uptrend Free Pattern Breakout Entry Stock Forecast - Newser
Should I hold or sell Delcath Systems Inc. stock in 2025Market-leading growth rates - jammulinksnews.com
How does Delcath Systems Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
Is Delcath Systems Inc. a growth stock or a value stockIdentify undervalued stocks poised to rally - jammulinksnews.com
How volatile is Delcath Systems Inc. stock compared to the marketGet professional advice for portfolio optimization - jammulinksnews.com
Delcath's Strategic Equity Incentive Programs and Their Implications for Talent Retention and Long-Term Growth - AInvest
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq L - GuruFocus
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DCTH Stock News - GuruFocus
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Delcath Systems Inc. Stock Analysis and ForecastRapid-fire capital growth - PrintWeekIndia
What analysts say about Delcath Systems Inc. stockAccelerated earnings growth - Autocar Professional
What drives Delcath Systems Inc. stock priceExceptional market performance - Autocar Professional
Delcath Systems Sets Q2 Earnings Date: Key Updates Expected on Liver Cancer Treatment Progress - Stock Titan
Is Delcath Systems Inc. a good long term investmentFastest-growing stock picks - Autocar Professional
Allegion Gears Up to Post Q2 Earnings: Here's What to Expect - The Globe and Mail
Uveal Melanoma Treatment Market Growth Accelerated - openPR.com
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):